Below are the financial statements of Charles River Laboratories, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 |
|---|---|---|
| Current assets | — | — |
| Cash and cash equivalents | 194.61a | 276.77a |
| Trade receivables and contract assets, net of allowances for credit losses of $18,301 and $25,722, respectively | 720.92a | 780.38a |
| Inventories | 278.54a | 380.26a |
| Prepaid assets | 103.21a | 87.88a |
| Other current assets | 105.8a | 83.38a |
| Total current assets | 1,403.07a | 1,608.66a |
| Assets | — | — |
| Property, plant and equipment, net | 1,604.01a | 1,639.74a |
| Venture capital and strategic equity investments | 218.35a | 243.81a |
| Operating lease right-of-use assets, net | 412.49a | 394.03a |
| Goodwill | 2,846.61a | 3,095.05a |
| Intangible assets, net | 723.4a | 864.05a |
| Deferred tax assets | 42.18a | 40.28a |
| Other assets | 278.23a | 309.38a |
| Total assets | 7,528.35a | 8,195a |
| Current liabilities | — | — |
| Accounts payable | 140.34a | 168.94a |
| Accrued compensation | 179.42a | 213.29a |
| Deferred revenue | 248.32a | 241.82a |
| Accrued liabilities | 232.01a | 227.83a |
| Other current liabilities | 194.01a | 203.21a |
| Total current liabilities | 994.1a | 1,055.08a |
| Liabilities | — | — |
| Long-term debt, net and finance leases | 2,240.21a | 2,647.15a |
| Operating lease right-of-use liabilities | 483.79a | 419.23a |
| Deferred tax liabilities | 106.96a | 191.35a |
| Other long-term liabilities | 195.21a | 223.19a |
| Total liabilities | 4,020.27a | 4,536a |
| Redeemable noncontrolling interests | 41.13a | 56.72a |
| Equity | — | — |
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | 0a | 0a |
| Common stock, $0.01 par value; 120,000 shares authorized; 51,141 shares issued and outstanding as of December 28, 2024 and 51,338 shares issued and outstanding as of December 30, 2023 | 0.51a | 0.51a |
| Additional paid-in capital | 1,966.24a | 1,905.58a |
| Retained earnings | 1,812.1a | 1,887.22a |
| Treasury stock, at cost, zero shares as of December 28, 2024 and December 30, 2023 | 0a | 0a |
| Accumulated other comprehensive loss | -317.35a | -196.43a |
| Total Charles River Laboratories International, Inc. equity | 3,461.5a | 3,596.88a |
| Nonredeemable noncontrolling interest | 5.45a | 5.39a |
| Total equity | 3,466.95a | 3,602.28a |
| Total liabilities, redeemable noncontrolling interests and equity | 7,528.35a | 8,195a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Charles River Laboratories’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.